7th ACCP Conference on Antithrombotic and Thrombolytic Therapy:

1
7th ACCP Conference on Antithrombotic and
Thrombolytic Therapy

• Evidence-Based Guidelines

2
Grade 1 Recommendations
RCT randomized controlled trial
3
Grade 2 Recommendations
RCT randomized controlled trial
4
Treatment of Venous Thromboembolic Disease
5
Initial Therapy for Acute DVT of the Leg

• We recommend that patients receive anticoagulants
  as soon as the diagnosis of DVT is confirmed
• Interim treatment should be started if suspicion
  is high and confirmation is delayed

6
Guidelines for Initial Treatment
7
Initial UFH or LMWH Therapy
8
Initial UFH or LMWH Therapy, continued
9
Systemic Thrombolysis as Initial Therapy
10
Systemic Thrombolysis as Initial Therapy,
continued
11
Long-term Therapy for DVT of the Leg
12
Long-term Therapy for DVT of the Leg, continued
Established LMWH regimens for long-term
treatment dalteparin, 200 IU/kg body weight qd
for 1 month, then 150 IU/kg qd or tinzaparin,
175 IU/kg body weight SC qd.
13
Long-term Therapy for DVT of the Leg, continued
14
Long-term Therapy for DVT of the Leg, continued
15
Initial Therapy for PE LMWH Or UFH Therapy
16
Initial Therapy for PE Thrombolytic Agents
17
Initial Therapy for PE Additional
Recommendations
18
Initial Therapy for PE Additional
Recommendations, continued
19
Long-Term Therapy for PE VKA Therapy
20
Long-Term Therapy for PEVKA Therapy, continued
21
Long-Term Therapy for PEVKA Therapy, continued
22
Postthrombotic Syndrome
23
Other Thrombotic Conditions
24
Other Thrombotic Conditions, continued
25
Other Thrombotic Conditions, continued